Source: The Next Web
Generare is banking on a specific arbitrage: that evolution has already solved the hard part of molecular design, and computational screening of microbial DNA is cheaper than traditional synthesis and screening. The claim of characterizing more novel small molecules in 2025 than “the rest of the field combined” either signals a real computational breakthrough or reflects a lowered bar for what counts as “novel”—either way, traditional drug discovery is saturated enough that well-capitalized VCs are funding companies that treat nature’s chemistry library as searchable infrastructure rather than inspiration. The shift from “discovering drugs” to “discovering which drugs nature already made” resets where value actually sits in biotech.